Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

This decision entails weighing the risk of new blood clots if treatment is discontinued against the risk of bleeding if it is continued. Common side effects of blood thinners include nosebleeds, blood ...